The Bayer Group continued its successful development in the third quarter of 2011. On a currency- and portfolio-adjusted basis, sales rose by 4.8% to €8.7 billion (reported: +1.0%; Q3 2010: €8.6 billion), with the emerging markets accounting for a disproportionately large share of growth. The operating result (EBIT) advanced by a substantial 94.9% to €1.1 billion (Q3 2010: €0.6 billion). » mehr